Literature DB >> 29396029

Prenatal treatment of ornithine transcarbamylase deficiency.

Yael Wilnai1, Yair J Blumenfeld2, Kristina Cusmano3, Susan R Hintz1, Deborah Alcorn1, William E Benitz1, William E Berquist1, Jonathan A Bernstein1, Ricardo O Castillo4, Waldo Concepcion5, Tina M Cowan6, Kenneth L Cox4, Deirdre J Lyell2, Carlos O Esquivel5, Margaret Homeyer1, Louanne Hudgins1, Melissa Hurwitz4, Jonathan P Palma1, Susan Schelley1, Vishnu Priya Akula1, Marshall L Summar3, Gregory M Enns7.   

Abstract

PURPOSE OF STUDY: Patients with neonatal urea cycle defects (UCDs) typically experience severe hyperammonemia during the first days of life, which results in serious neurological injury or death. Long-term prognosis despite optimal pharmacological and dietary therapy is still poor. The combination of intravenous sodium phenylacetate and sodium benzoate (Ammonul®) can eliminate nitrogen waste independent of the urea cycle. We report attempts to improve outcomes for males with severe ornithine transcarbamylase deficiency (OTCD), a severe X-linked condition, via prenatal intravenous administration of Ammonul and arginine to heterozygous carrier females of OTCD during labor. METHODS USED: Two heterozygote OTCD mothers carrying male fetuses with a prenatal diagnosis of OTCD received intravenous Ammonul, arginine and dextrose-containing fluids shortly before birth. Maintenance Ammonul and arginine infusions and high-caloric enteral nutrition were started immediately after birth. Ammonul metabolites were measured in umbilical cord blood and the blood of the newborn immediately after delivery. Serial ammonia and biochemical analyses were performed following delivery. SUMMARY OF
RESULTS: Therapeutic concentrations of Ammonul metabolites were detected in umbilical cord and neonatal blood samples. Plasma ammonia and glutamine levels in the postnatal period were within the normal range. Peak ammonia levels in the first 24-48h were 53mcmol/l and 62mcmol/l respectively. The boys did not experience neurological sequelae secondary to hyperammonemia and received liver transplantation at ages 3months and 5months. The patients show normal development at ages 7 and 3years.
CONCLUSION: Prenatal treatment of mothers who harbor severe OTCD mutations and carry affected male fetuses with intravenous Ammonul and arginine, followed by immediate institution of maintenance infusions after delivery, results in therapeutic levels of benzoate and phenylacetate in the newborn at delivery and, in conjunction with high-caloric enteral nutrition, prevents acute hyperammonemia and neurological decompensation. Following initial medical management, early liver transplantation may improve developmental outcome.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Liver transplantation; Neurological outcome; Nitrogen-scavenging medication; OTC deficiency; Prenatal treatment

Mesh:

Substances:

Year:  2018        PMID: 29396029     DOI: 10.1016/j.ymgme.2018.01.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  3 in total

1.  Peripheral venous route for administration of ammonul infusion for treatment of acute hyperammonemia. An experience from a tertiary center in Saudi Arabia.

Authors:  Amal M Alhashem; Rihab M Salih; Aida I Al-Aqeel; Sarar Mohamed
Journal:  Saudi Med J       Date:  2020-01       Impact factor: 1.484

2.  Ornithine transcarbamylase deficiency and pregnancy: A case series and review of recommendations.

Authors:  Gabriella Pinho; Gabriela Ross; Kaila Krishnamoorthy; Christina Kresge; Ling Yu Shih; Joseph J Apuzzio; Shauna F Williams
Journal:  Case Rep Womens Health       Date:  2022-01-30

3.  Clinical and molecular characteristics of 69 Chinese patients with ornithine transcarbamylase deficiency.

Authors:  Deyun Lu; Feng Han; Wenjuan Qiu; Huiwen Zhang; Jun Ye; Lili Liang; Yu Wang; Wenjun Ji; Xia Zhan; Xuefan Gu; Lianshu Han
Journal:  Orphanet J Rare Dis       Date:  2020-12-03       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.